1 of 1
Story summary
- Eli Lilly CEO Dave Ricks opposed the White House's plan to codify 'most favored nation' drug pricing into law on November 6, 2025.
- Lilly and other drugmakers previously agreed to charge U.S. prices similar to those in other wealthy nations, addressing concerns raised by U.S. President Donald Trump.
- The White House is urging Congress to formalize aspects of these deals, but the draft text remains undisclosed.
